ES2190373A1 - Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero. - Google Patents

Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Info

Publication number
ES2190373A1
ES2190373A1 ES200102725A ES200102725A ES2190373A1 ES 2190373 A1 ES2190373 A1 ES 2190373A1 ES 200102725 A ES200102725 A ES 200102725A ES 200102725 A ES200102725 A ES 200102725A ES 2190373 A1 ES2190373 A1 ES 2190373A1
Authority
ES
Spain
Prior art keywords
hydroxy
prevention
treatment
acid
trifluorometilbenzoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200102725A
Other languages
English (en)
Other versions
ES2190373B1 (es
Inventor
Rafanell Julian Garcia
Orti Genis Munoz
Ramirez Jose Carlos Navas
Pulido Jose Ignacio Izquierdo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102725A priority Critical patent/ES2190373B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to AU2002352228A priority patent/AU2002352228A1/en
Priority to MXPA04005450A priority patent/MXPA04005450A/es
Priority to ARP020104736A priority patent/AR037728A1/es
Priority to PCT/EP2002/013862 priority patent/WO2003047562A1/en
Priority to CA002471794A priority patent/CA2471794A1/en
Priority to EP02787920A priority patent/EP1453499A1/en
Priority to KR1020047008791A priority patent/KR20050044742A/ko
Priority to BR0214779-3A priority patent/BR0214779A/pt
Priority to US10/313,498 priority patent/US20030162756A1/en
Priority to JP2003548818A priority patent/JP2005515993A/ja
Publication of ES2190373A1 publication Critical patent/ES2190373A1/es
Priority to NO20042785A priority patent/NO20042785L/no
Application granted granted Critical
Publication of ES2190373B1 publication Critical patent/ES2190373B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al uso del ácido 2-hidroxi- o 2- acetiloxi-4-trifluorometilbenzoico, respectivamente, para el tratamiento o prevención del deterioro cognitivo ligero (DCL) en mamíferos, especialmente en seres humanos. Asimismo, la presente invención se refiere también al uso del ácido 2-hidroxi- ó 2- acetiloxi-4-trifluorometilbenzoico, respectivamente, para retrasar o prevenir la conversión de DCL a demencia, especialmente a enfermedad de Alzheimer.
ES200102725A 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero. Expired - Fee Related ES2190373B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200102725A ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
BR0214779-3A BR0214779A (pt) 2001-12-07 2002-12-06 Uso de derivados de acido 2-hidróxi ou 2-acetilóxi-4trifluormetilbenzóico como um agente para o tratamento e a prevenção de deterioração cognitiva moderada
ARP020104736A AR037728A1 (es) 2001-12-07 2002-12-06 Un compuesto acido 2-hidroxi- o 2-acetiloxi-4-trifluoremetilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero
PCT/EP2002/013862 WO2003047562A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
CA002471794A CA2471794A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
EP02787920A EP1453499A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoro-methylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
AU2002352228A AU2002352228A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
MXPA04005450A MXPA04005450A (es) 2001-12-07 2002-12-06 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agentes para el tratamiento y prevencion del deterioro cognitivo ligero.
US10/313,498 US20030162756A1 (en) 2001-12-07 2002-12-06 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
JP2003548818A JP2005515993A (ja) 2001-12-07 2002-12-06 軽度認識障害の治療及び予防剤としての2−ヒドロキシ又は2−アセチルオキシ−4−トリフルオロメチル安息香酸誘導体の使用
KR1020047008791A KR20050044742A (ko) 2001-12-07 2002-12-06 경증 인식 장애의 치료제 및 예방제로서의 2-하이드록시또는 2-아세틸옥시-4-트리플루오로메틸벤조산 유도체의이용 방법
NO20042785A NO20042785L (no) 2001-12-07 2004-07-01 Anvendelse av 2-hydroksy- eller 2-acetyloksy-4-trifluormetylbenzosyrederivater som et middel for behandlingen og forebyggingen av mild kognitiv svekkelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102725A ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Publications (2)

Publication Number Publication Date
ES2190373A1 true ES2190373A1 (es) 2003-07-16
ES2190373B1 ES2190373B1 (es) 2004-10-16

Family

ID=8499682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200102725A Expired - Fee Related ES2190373B1 (es) 2001-12-07 2001-12-07 Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Country Status (12)

Country Link
US (1) US20030162756A1 (es)
EP (1) EP1453499A1 (es)
JP (1) JP2005515993A (es)
KR (1) KR20050044742A (es)
AR (1) AR037728A1 (es)
AU (1) AU2002352228A1 (es)
BR (1) BR0214779A (es)
CA (1) CA2471794A1 (es)
ES (1) ES2190373B1 (es)
MX (1) MXPA04005450A (es)
NO (1) NO20042785L (es)
WO (1) WO2003047562A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
WO2010134477A1 (ja) * 2009-05-18 2010-11-25 Jsr株式会社 感放射線性樹脂組成物及び化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061030A1 (es) * 1998-05-27 1999-12-02 J. Uriach & Cia, S.A. USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061030A1 (es) * 1998-05-27 1999-12-02 J. Uriach & Cia, S.A. USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LËPEZ-POUSA, S. y col. Triflusal en la prevención de la demencia vascular. Rev. Neurol., 1997, Vol. 25, Nö 146, páginas 1525-1528. Todo el documento, en especial, resumen y Discusión (página 1527). *

Also Published As

Publication number Publication date
MXPA04005450A (es) 2005-04-19
AR037728A1 (es) 2004-12-01
ES2190373B1 (es) 2004-10-16
JP2005515993A (ja) 2005-06-02
US20030162756A1 (en) 2003-08-28
WO2003047562A1 (en) 2003-06-12
CA2471794A1 (en) 2003-06-12
NO20042785L (no) 2004-07-01
EP1453499A1 (en) 2004-09-08
AU2002352228A1 (en) 2003-06-17
KR20050044742A (ko) 2005-05-12
BR0214779A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
BR0211905A (pt) Dialdeìdos de rapamicina
PT921785E (pt) Combinacao de enzimas protease acidas e tampoes acidicos e suas utilizacoes
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
DK1082962T3 (da) Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B
PY990129A (es) Bromhidrato de eletriptan monohidratado
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
BR0116077A (pt) Micropartìculas com perfil de liberação aperfeiçoado e processos para produção das mesmas
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
ES2190373A1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
BR9807312A (pt) Derivados de (4-piperidinil)-1h-2-benzopirano úteis como agentes antipsicóticos
TW200503675A (en) Combination of phenylcarboxamides with blockers of the Ikr channel and their use for the treatment of atrial arrhythmias
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2190373B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180803

FD2A Announcement of lapse in spain

Effective date: 20180807